AdventHealth Tampa is proud to announce the accreditation of its new Obstetrics and Gynecology Residency Program, helping improve access to women’s healthcare in the Tampa Bay region.
AdventHealth Tampa Launching New OB/GYN Residency Program Read More »
The New England Journal of Medicine published detailed results from Eli Lilly and Company’s phase 2a study of peresolimab in rheumatoid arthritis, in which peresolimab met the primary endpoint for efficacy and had similar rates of adverse events between peresolimab and placebo arms.
SwanBio Therapeutics, a gene therapy company advancing AAV-based therapies for the treatment of devastating, inherited neurological conditions, presented preliminary data from primate studies of AAV capsids that outperform the commonly used AAV9 capsid.
Vifor Fresenius Medical Care Renal Pharma and Cara Therapeutics, Inc. announced that England’s National Institute for Health and Care Excellence has recommended Kapruvia® for the treatment of moderate-to-severe CKD-associated pruritus in adult patients on haemodialysis.
GenScript’s new life-science building in Zhenjiang, Jiangsu, China spans 91,310 sq. ft. and is ISO 9001 certified; highly automated clean-room facilities offer fast-turnaround, high-purity oligonucleotide and peptide synthesis service for R&D and preclinical applications.
GenScript Expands Peptide and Oligonucleotide Production Facility in China Read More »
Asieris Pharmaceuticals, a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced a strategic collaboration with UroViu Corporation.
Be Biopharma, Inc., a company pioneering the discovery and development of Engineered B Cell Medicines, will present preclinical research showing the precise genome engineering of human B cells to express diverse therapeutic proteins using the company’s proprietary platform.
ImaginAb, Inc. announced lead selection and progression to IND-enabling studies of IAB56, a minibody designed to target the αvβ6 integrin for use as Lu-177 radiopharmaceutical therapy in solid tumors.
Adicet Bio, Inc. announced preclinical data highlighting ADI-270, an armored allogeneic “off-the-shelf” gamma delta CAR T cell therapy candidate targeting CD70+ cancers, at the 26th Annual Meeting of the American Society of Gene & Cell Therapy taking place from May 16-20, 2023, in Los Angeles, CA.
Syngenta Group has withdrawn its STAR Market IPO application and will immediately apply for a public listing on the main board at the Shanghai Stock Exchange.
